Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Specimen Handling 613pembrolizumab 568Magnetic Resonance Spectroscopy 538Carboplatin 429Cyclophosphamide 381Cisplatin 374Biopsy 355Paclitaxel 312Nivolumab 307Gemcitabine 302Radiotherapy 260Bevacizumab 237Dexamethasone 213fludarabine 207Docetaxel 189durvalumab 181atezolizumab 175Oxaliplatin 171Rituximab 167Fluorouracil 167venetoclax 166Pemetrexed 164Doxorubicin 161Capecitabine 158Radiation 157Radiosurgery 147Etoposide 138Leucovorin 134Ipilimumab 134Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × N-monoacetylcystine × 90 days × Clear all
NCT04481048 2026-06-05

DoDNAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
25 enrolled 12 charts
CNS

Attention Deficit Disorder with Hyperactivity, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡